company background image
PCIB logo

PCI Biotech Holding OB:PCIB Stock Report

Last Price

NOK 1.29

Market Cap

NOK 48.3m

7D

5.7%

1Y

-34.3%

Updated

06 Feb, 2025

Data

Company Financials

PCIB Stock Overview

A biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. More details

PCIB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

PCI Biotech Holding ASA Competitors

Price History & Performance

Summary of share price highs, lows and changes for PCI Biotech Holding
Historical stock prices
Current Share PriceNOK 1.29
52 Week HighNOK 3.50
52 Week LowNOK 1.10
Beta1.61
1 Month Change-6.50%
3 Month Change-8.87%
1 Year Change-34.31%
3 Year Change-77.20%
5 Year Change-97.84%
Change since IPO-92.81%

Recent News & Updates

Recent updates

We're Keeping An Eye On PCI Biotech Holding's (OB:PCIB) Cash Burn Rate

Aug 05
We're Keeping An Eye On PCI Biotech Holding's (OB:PCIB) Cash Burn Rate

We Think PCI Biotech Holding (OB:PCIB) Needs To Drive Business Growth Carefully

Apr 21
We Think PCI Biotech Holding (OB:PCIB) Needs To Drive Business Growth Carefully

We're Hopeful That PCI Biotech Holding (OB:PCIB) Will Use Its Cash Wisely

Dec 16
We're Hopeful That PCI Biotech Holding (OB:PCIB) Will Use Its Cash Wisely

We're Not Very Worried About PCI Biotech Holding's (OB:PCIB) Cash Burn Rate

Apr 09
We're Not Very Worried About PCI Biotech Holding's (OB:PCIB) Cash Burn Rate

What Type Of Shareholders Own The Most Number of PCI Biotech Holding ASA (OB:PCIB) Shares?

Feb 15
What Type Of Shareholders Own The Most Number of PCI Biotech Holding ASA (OB:PCIB) Shares?

PCI Biotech Holding (OB:PCIB) Is In A Good Position To Deliver On Growth Plans

Dec 22
PCI Biotech Holding (OB:PCIB) Is In A Good Position To Deliver On Growth Plans

Shareholder Returns

PCIBNO BiotechsNO Market
7D5.7%-1.4%-1.6%
1Y-34.3%-55.3%10.7%

Return vs Industry: PCIB exceeded the Norwegian Biotechs industry which returned -54.9% over the past year.

Return vs Market: PCIB underperformed the Norwegian Market which returned 10% over the past year.

Price Volatility

Is PCIB's price volatile compared to industry and market?
PCIB volatility
PCIB Average Weekly Movement16.9%
Biotechs Industry Average Movement15.3%
Market Average Movement5.1%
10% most volatile stocks in NO Market12.0%
10% least volatile stocks in NO Market2.6%

Stable Share Price: PCIB's share price has been volatile over the past 3 months compared to the Norwegian market.

Volatility Over Time: PCIB's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.

About the Company

FoundedEmployeesCEOWebsite
20076Ronny Skuggedalwww.pcibiotech.com

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company’s technology platform consists of a proprietary small molecule photosensitiser (fimaporfin) and a light source; and develops photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities, as well as photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing. It also explores for intratumoural immunotherapy therapeutics that identifies novel treatment combinations to overcome resistance to immune-checkpoint inhibitors and safety-issues associated with treatments; and develops nucleic acid therapeutics to improve the treatment of dermatological diseases.

PCI Biotech Holding ASA Fundamentals Summary

How do PCI Biotech Holding's earnings and revenue compare to its market cap?
PCIB fundamental statistics
Market capNOK 48.30m
Earnings (TTM)-NOK 15.91m
Revenue (TTM)NOK 6.00m

8.1x

P/S Ratio

-3.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PCIB income statement (TTM)
RevenueNOK 6.00m
Cost of RevenueNOK 0
Gross ProfitNOK 6.00m
Other ExpensesNOK 21.91m
Earnings-NOK 15.91m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Feb 27, 2025

Earnings per share (EPS)-0.43
Gross Margin100.00%
Net Profit Margin-265.24%
Debt/Equity Ratio0%

How did PCIB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 05:39
End of Day Share Price 2025/02/06 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PCI Biotech Holding ASA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hans BohnBeringer Finance AB